Par Drugs and Chemicals receives WHO-GMP certificate

The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3

Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine

The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY

Briefs: Kilitch Drugs India, Family Care Hospitals and Krishna Institute of Medical Sciences

Krishna Institute of Medical Sciences to consider raising Rs. 300 crores

CDSCO and State Drugs Control Administration commence joint inspection of drug manufacturing units

A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940

Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business

Unichem Laboratories sale its stake in Optimus Drugs

The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.

PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.

PIB: Quality control of Ayush drugs

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.